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Objective: To evaluate adherence to national guidelines for follow-up, and assess residual 23 
and recurrent disease after treatment for cervical intraepithelial neoplasia grade 2 or worse 24 
(CIN2+). 25 
Study design: In a case-series design women aged 25-69 years treated for primary CIN2+ in 26 
2006-2011 (n=752) were followed through August 9, 2019 for residual or recurrent disease, 27 
i.e., CIN2+ diagnosed before or after, respectively, two consecutive, normal post-treatment 28 
cytology results. We used the Chi-Square test to assess predictive factors of adherence to 29 
post-treatment follow-up and residual disease, and survival analyses to assess the cumulative 30 
incidence of residual and recurrent disease.  31 
Results: Strict adherence to post-treatment follow-up was low (59%). However, 702 (95%) 32 
women attended at least one post-treatment follow-up visit within the suggested time window. 33 
Forty-two women (5.6%) were diagnosed with residual disease, 38 (91%) of whom were 34 
diagnosed within 2 years of treatment. Among the 637 (85%) women with two consecutive, 35 
normal post-treatment cytology results, cumulative incidence of recurrent disease was 1.0 36 
(95% confidence interval [CI]: 0.2-1.8) and 2.5 (95% CI: 1.2-3.8) per 100 women-years 37 
within 42 and 78 months of treatment, respectively. Three women with residual and two with 38 
recurrent disease were diagnosed with cervical cancer within 78 months of treatment. Women 39 
with not-free resection margins at treatment had a significantly increased risk of residual and 40 
recurrent disease. Using a 2-year definition for residual disease would misclassify 3 of 5 41 
cancer cases as recurrent disease when they were true cases of residual disease. 42 
Conclusions: This study emphasizes the importance of properly distinguishing between 43 
residual and recurrent disease after treatment for CIN2+. Many women with residual disease 44 
could benefit from an earlier colposcopy, cervical biopsy, or diagnostic conization during 45 
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post-treatment follow-up in order to detect occult cervical cancer. The cumulative incidence 46 
of recurrent disease within 78 months of treatment was low. 47 




The organized cervical cancer screening program in Norway was initiated in 1995. The 50 
program covers women aged 25-69 years, who are recommended to undergo screening by 51 
cervical cytology every 3 years, with the intention to detect and treat precancerous lesions and 52 
thereby reduce cervical cancer incidence and mortality. For many years, the loop 53 
electrosurgical excision procedure has been the method of choice to treat precancerous lesions 54 
(1). As the risk of cervical cancer remains high up to 20 years after treatment (2-4), it is 55 
important to assess treatment effectiveness before sending women back to the regular 56 
screening program.  57 
During the period covered in this study, Norwegian guidelines recommended different 58 
post-treatment follow-up algorithms based on resection margins: women with free margins 59 
and two consecutive, normal cytology results within 4-18 months of treatment can return to 60 
the regular screening program; women with non-free margins should have two consecutive, 61 
normal cytology results within 12 months, as well as one normal cytology result each year for 62 
4 years before returning to the regular screening program (5). Women with abnormal cytology 63 
results during post-treatment follow-up are referred according to the follow-up algorithm of 64 
the regular screening program. 65 
Most previous studies defined residual disease as cervical intraepithelial neoplasia grade 2 66 
or worse (CIN2+) diagnosed within 2 years of treatment, and recurrent disease as CIN2+ 67 
diagnosed thereafter (6,7), or did not distinguish between residual and recurrent disease when 68 
assessing treatment effectiveness (8-11).  Treated women with minor cytological 69 
abnormalities (atypical squamous cells of undetermined significance or low-grade squamous 70 
intraepithelial lesions), or intermittent normal or unsatisfactory cytology results during post-71 
treatment follow-up, could be under surveillance for years before residual or recurrent disease 72 
is detected or they are returned to the regular screening program. Using a threshold of 2 years 73 
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has inevitably introduced misclassification of residual and recurrent disease, which 74 
overestimates the recurrence rate and underestimates the real number of treatment failures. 75 
In the present study, we evaluated adherence to national guidelines for follow-up and assessed 76 
residual and recurrent disease after treatment for CIN2+ in the two northernmost counties in 77 
Norway (Troms and Finnmark) using a historical prospective case-series design.  78 
 79 
Material and Methods  80 
The Department of Pathology, University Hospital of North Norway, Tromsø, is the only 81 
laboratory that performs both cytological and histological assessments for the residents of 82 
Troms and Finnmark counties, thus its clinical database, SymPathy, captures all information 83 
on screening history, treatment, and follow-up. Using that database, we identified 852 women 84 
who received treatment for primary CIN2+ from January 1, 2006 through December 31, 2011. 85 
We excluded women outside the target age group of the screening program (66 women aged 86 
17-24 years and 11 aged 70-89 years), women with a diagnosis of cervical cancer in 87 
biopsies/cone specimens (n=20) and women who had a direct hysterectomy within 6 months 88 
of treatment (n=3), leaving 752 women in the study sample.  89 
We categorized age into three (25-39, 40-54, and 55-69 years) and time period into two 90 
groups (2006-08 and 2009-11). Histological diagnoses in biopsies and cone specimens were 91 
recorded as CIN1, CIN2, CIN3 (including adenocarcinoma in situ), and cervical cancer. 92 
Resection margins were categorized as free or not free, with the latter category including 93 
missing and inconclusive assessment.  94 
We applied a pragmatic approach when analyzing adherence to post-treatment follow-up, 95 
without considering resection margins. In addition, we expanded the window for adherence to 96 
post-treatment follow-up from 4-18 months to 3-18 months, as many women attended their 97 
first follow-up visit 3-4 months after treatment. Adherence was defined attending two follow-98 
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up visits within the expanded post-treatment follow-up window. Non-adherence was defined 99 
as attending only one follow-up visit or none at all. In addition, women who attended their 100 
first follow-up visit before or within the expanded post-treatment follow-up window but had 101 
subsequent visits thereafter (after 18 months) were categorized as non-adherent, as were those 102 
who had first and subsequent follow-up visits after 18 months. If a woman had a cytology 103 
sample and a biopsy collected at the same follow-up visit, the histological outcome was used.                                                                                              104 
We defined residual disease as histologically confirmed CIN2+ diagnosed before two 105 
consecutive, normal post-treatment cytology results. Women awaiting further follow-up for 106 
abnormal post-treatment cytology results were classified as having "incomplete follow-up" at 107 
study end. Recurrent disease was defined as histologically confirmed CIN2+ diagnosed after 108 
two consecutive, normal post-treatment cytology results. Post-treatment follow-up time was 109 
calculated as the time in months between treatment and a histological outcome of CIN2+ or 110 
date of last post-treatment follow-up visit. 111 
All analyses were performed in SPSS version 24.0 with a Chi-square test, Fisher's exact 112 
test, and survival analyses. P-values <0.05 were considered statistically significant. Follow-up 113 
ended on August 9, 2019. We analyzed residual disease within 24 months of treatment, and 114 
residual and recurrent disease within 42 and 78 months of treatment. Seventy-eight month of 115 
follow-up resembles two screening rounds from treatment including a 6 month delay as 116 
practiced by NCR (36+36+6 months). 117 
The Regional Committee for Medical and Health Research Ethics, North Norway, has 118 
evaluated the protocol as a quality assurance study fulfilling the requirements for data 119 
protection procedures within the department (2015/2479/REK Nord). The Patient 120 




Results                                                                                                                                             123 
Mean age at treatment was 37 years (range 25-68 years), and the majority of women were 124 
treated for CIN grade 2 or 3 (97%). Resection margins were not free in one-third of cone 125 
specimens. There were no significant differences in distribution of age, most severe histology, 126 
or status of resection margins by time period (Table 1).  127 
In total, 443 women (58.9%) were adherent to post-treatment follow-up. Among non-128 
adherent women, eight (1.1%) attended no post-treatment follow-up visits, whereas 26 129 
women (3.5%) had only one post-treatment follow-up visit (Table 2). Nearly 97% of the 130 
women attended at least one post-treatment follow-up visit during our extended post-131 
treatment follow-up window. There was no significant association between age at treatment, 132 
most severe histology, status of resection margins and adherence to post-treatment follow-up. 133 
Within 78 months of treatment, 42 women (CIN2=13, CIN3=26, cervical cancer=3) 134 
(5.6%) were diagnosed with residual disease (Table 3). In 38 (91%) of these women, the 135 
diagnoses occurred within 2 years of treatment. Among women with residual disease, 136 
resection margins were not free in 54% of women with residual CIN2 and in 73% of women 137 
with residual CIN3. The cumulative incidence of residual disease (CIN2+) increased from 138 
10.4 to 11.9 per 100 women-months among women with not-free resection margins within 24 139 
and 78 months of treatment, compared to an increase from 2.3 to 3.1 per 100 women-months 140 
among women with free resection margins (p<0.001). Three women were diagnosed with 141 
residual cervical cancer within 43-71 months of treatment (Table 4). At 78 months post-142 
treatment, 9.7% of women remained unresolved due to incomplete follow-up (8.6%) or non-143 
attendance to post-treatment follow-up visits (1.1%).  144 
Eighty-five percent of the women (n=637) returned to the regular screening program 145 
within 78 months of treatment, most of whom had free margins at treatment (69%). The 146 
cumulative incidence of recurrent disease was 1.0 (95% confidence interval [CI]: 0.2-1.8) and 147 
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2.5 (95% CI: 1.2-3.8) per 100 women-months within 42 and 78 months of treatment, 148 
respectively.  In total, 14 women developed recurrent disease (CIN2=10, CIN3=2, cervical 149 
cancer=2), all of whom were diagnosed more than 2 years after treatment. Women with not-150 
free margins had a significantly increased risk of recurrent disease (p=0.01) despite a low 151 
cumulative incidence.  152 
Among the five cervical cancer cases, four had been diagnosed with CIN3 at primary 153 
treatment. Both recurrent cases of cervical cancer were adherent to post-treatment follow-up. 154 
However, the residual cases of cervical cancer had a delay in their diagnosis due to late 155 
referral and/or incomplete colposcopies (Table 4).  156 
 157 
Comment                                                                                                                        158 
The adherence to guidelines for post-treatment follow-up we observed was higher than that in 159 
most studies, but it was still not satisfactory. Our residual disease estimate of 5.6% is lower 160 
than that reported in most other studies on treatment failure (6-11), but it may be 161 
underestimated, as 8.6% of the women were awaiting further follow-up at study end. Among 162 
women who returned to the screening program, the cumulative incidence of recurrent disease 163 
within 78 months of treatment was low.  164 
Few studies have reported adherence with guidelines for post-treatment follow-up. Barken 165 
et al. (12) followed 45 984 Danish women for 5 years and assessed adherence at 15-month 166 
intervals. Ninety percent of their study sample attended at least one visit within 15 months of 167 
treatment, but only 40% had yearly Pap smears as recommended in Danish guidelines. This is 168 
in line with results on 2-year follow-up in studies from the US (13), the Netherlands (14), and 169 
Italy (15). Another study (16) from the UK found that over 20% of women did not attend 170 
follow-up visits within the recommended 12 months. A recent study from Australia (17) 171 
evaluated adherence within 12 and 24 months of treatment and found that over half of those 172 
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who attended a first follow-up visit did not attend a second follow-up visit. In our study, 95% 173 
of the women attended at least one follow-up visit within the recommended time window. In 174 
agreement with a study from England by Soutter et al. (16), but in contrast to other studies 175 
(11, 13, 15), we had a low rate of loss to follow-up.  176 
Residual/recurrent rates of CIN2+ assessed within 4-6 months (18-20), 12 months (21) or 177 
within 2 years of treatment (6, 7) have ranged from 1-10% (6, 7, 18-22). We observed 178 
residual disease in 5.6% of our study sample within 78 months of treatment, which is 179 
consistent with a previous study that used a similar definition of residual and recurrent disease 180 
(22), and non-significantly lower than the estimate from a meta-analysis of 24 studies with at 181 
least 18 months of post-treatment follow-up (6.6%, 95% CI: 4.9-8.4) (23).  182 
As reported by others, we confirmed that women with not-free resection margins have 183 
higher rates of residual disease (9, 10, 18, 19, 22, 23) and a higher incidence of recurrent 184 
disease (22). Our study did not show that CIN3 or older age were predictors of 185 
residual/recurrent disease.  186 
Follow-up of abnormal post-treatment cytology results and specimen collection for 187 
histologic evaluation takes time and may delay the diagnosis of residual disease for years. In 188 
our study 9% of cases of residual disease were diagnosed after 2 years of treatment, while 189 
8.6% still had an incomplete follow-up at study end. Many of these women had adverse post-190 
treatment cytology outcomes that should have led to an earlier biopsy, including the three 191 
cases of residual cervical cancer. We could not decide whether this was a patient delay, a 192 
doctor delay, or a combination of the two. 193 
If we had used a 2-year cut-off for residual disease, the number of recurrent cases of CIN3 194 
would increase from 2 to 3, while the number cervical cancer cases would increase from 2 to 195 
5 cases. This misclassification of cervical cancer increased the incidence of recurrent cervical 196 
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cancer from 52 to 130 per 100 000 women-years within 78 months of treatment . This stress 197 
the importance of a flawless definition of post-treatment residual and recurrent disease  198 
Follow-up after treatment for CIN2+ has been studied for years, but there is still no 199 
consensus on tests, intervals, or duration of follow-up. Previous studies used various follow-200 
up algorithms, and in recent years several authors have recommended the use of human 201 
papillomavirus (HPV) testing, either alone or as a co-test with cytology (23-26). Persistent 202 
HPV infection after treatment for CIN2+ has been shown to be the most important predictor 203 
of residual/recurrent disease (23). A study from the Netherlands found that co-testing led to 204 
fewer unnecessary colposcopy referrals, as co-testing showed higher specificity for the 205 
detection of residual/recurrent CIN2+ compared to cytology alone, while no difference in 206 
sensitivity was observed (27). However, Strander et al. followed women for 14 years after 207 
treatment and found that HPV testing 6-12 months after treatment was of limited value in 208 
predicting residual/recurrent CIN2+, as many of the women who developed CIN2+ more than 209 
2 years after treatment were HPV-negative at short-term post-treatment follow-up (28).  210 
Clearance rates of HPV infection after treatment varied from 45-50% at 3-6 months to 1-211 
8% at 24 months after treatment (8,29), indicating that clearance may take years. Many post-212 
treatment HPV studies had only one follow-up visit, or a follow-up interval that was too short 213 
to determine the importance of HPV testing in treatment algorithms. Co-testing with HPV 214 
testing and a cytology remains uncontroversial when both tests are negative or positive. 215 
However, if samples are collected too close to treatment, co-testing will inevitably lead to 216 
unnecessary follow-up due to discordant HPV (positive) and cytology (normal) results. A 217 
positive HPV test may also be due to a re-infection from an HPV-positive partner. Postponing 218 
HPV testing to at least 6 months after treatment, and implementing reflex testing in all cases 219 




Table 5 summarizes post-treatment follow-up guidelines in selected countries. The main 222 
difference across countries is the timing of the first post-treatment follow-up visit. Very few 223 
studies report cancer within the first post-treatment follow-up year (2).  In our study (Table 4) 224 
and other studies (3), the first case of cervical cancer was diagnosed 2-3 years after treatment. 225 
The other issue with co-testing in post-treatment follow-up is the persistence of HPV 226 
infections. The shorter the time interval from treatment, the more likely it is that the HPV test 227 
will be positive. As HPV infections wane over time; a 12-month interval before a first post-228 
treatment follow-up visit will reduce over-diagnosing and unnecessary follow-up due to a 229 
false-positive HPV test in the presence of normal cytology or minor cytological abnormalities. 230 
The timing of the second post-treatment follow-up visit varies across countries. In the US, 231 
Australia, and Finland, a 24-month visit is recommended, while the UK, Denmark, and 232 
Sweden recommend returning to screening when the first co-test is negative. As most studies 233 
on this topic are short-term, we need to await risk assessment evaluations of the new 234 
guidelines in prospective studies before a more global follow-up regimen can be agreed upon 235 
(31). Except for Denmark, information about resection margins was not a parameter for 236 
follow-up evaluation in updated post-treatment follow-up guidelines (Table 5), as a meta-237 
analysis including 97 studies concluded that a positive HPV test result outweighed 238 
information on resection margins in the prediction of treatment failure (23). All new 239 
algorithms for follow-up make a clear distinction between residual and recurrent disease, as 240 
the timing of return to the regular screening program is determined by one, or two 241 
consecutive, negative co-tests, where the first co-test occurs within 6 or 12 months of 242 
treatment, the subsequent co-test occurs at 12 or 24 months (Table 5). 243 
The strengths of the present study were the large, population-based sample size and the 244 
long-term follow-up after treatment. Furthermore, we used firm definitions for residual and 245 
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recurrent disease. Limitations include the retrospective study design and the lack of consistent 246 
HPV testing during follow-up.  247 
 248 
Conclusion                                                                                                                               249 
Adherence to follow-up guidelines after treatment for CIN2+ was low. It is important to 250 
discriminate between residual and recurrent disease in post-treatment follow-up. Most women 251 
with the residual disease were diagnosed within 2 years; however, the three residual cancer 252 
cases were diagnosed at a later time point. Few women developed recurrent disease within 78 253 
months of treatment.  254 
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Table 2: Adherence to post-treatment follow-up guidelines by status of resection margins 371 
(%) 372 












Free Not-free Total 
  N=504 N=248 N=752 
  % % % 
Non-adherent      
No follow-up   1.2 0.8 1.1 
1 follow-up visit  
1-2 mo.  0.8 0.4 0.7 
3-18 mo.  3.2 1.6 2.7 
≥19 mo.   0.4 0.1 
≥2 follow-up visits  
≥3 mo. ≥19 mo. 20.0 14.9 18.4 
1-2 mo. ≤18 mo. 14.9 17.7 15.8 
1-2 mo. ≥19 mo. 2.2 1.6 2.0 
≥19 mo. ≥19 mo. 0.6  0.4 
Adherent                ≥2 follow-up visits ≥3 mo. ≤18 mo. 57.1 62.5 58.9 
 373 
 374 
  375 
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Table 3: Status within 24, 42, and 78 months of treatment 376 









Non-attenders  1.1 1.1 1.1 















Back to regular 
screening program 
70.2 79.8 84.7 
Total  100 100 100 
CIN1: cervical intraepithelial neoplasia grade 1;                                                                                                     377 
CIN2: cervical intraepithelial neoplasia grade 2;                                                                               378 
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Table 4 Status at conization, adherence to follow-up, and histology/stage   385 
  for the five cervical cancer cases. 386 
 387 
At conization Follow-up Cervical cancer 
Age  Histo- 
logy  
Resection            
margins 







Months         
to 
diagnosis 
Histology                                                                          Stage







































CIN1: cervical intraepithelial neoplasia grade 1;                                                                                    388 
CIN2: cervical intraepithelial neoplasia grade 2;                                                                                              389 
CIN3: cervical intraepithelial neoplasia grade 3 390 
 391 
  392 
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Table 5: Algorithms for post-treatment surveillance from select countries. 393 
Country  Year  Recommendation Reference  
USA 
(ASCCP) 
2012 o Co-test at 12 and 24 months.  
o If 12 and 24 months tests are negative, 
retesting in 3 years  
o If any test is abnormal, colposcopy 
with biopsy 
L.S. Massad, M.H. Einstein, W.K. Huh 
et al. ASCCP Consensus Guidelines 
Conference. J Low Genital Tract Dis 
2013;17:S1-S27 
Denmark  2012 o Co-test + assessment of resection margins at 6 
months  
o If all normal, return to regular 
screening program  
o If any positive, co-test at 12 months  
http://www.sst.dk/~/media/B1211EAF
EDFB47C5822E883205F99B79.ashx  
Norway 2015 o Co-test at 6 and 12 months  
o If negative HPV and normal cytology, 
co-test at 12 months  
o Otherwise follow-up dependent upon 






UK 2016 o Co-test at 6 months  
o If pap negative/borderline/low-grade 
and HPV-negative, return to regular 
screening program 
o If the HPV test is positive, referral to 
colposcopy.  
o If pap high-grade, referral to 





Australia  2016 o Co-test at 12 months and annually thereafter, 
until two negative co-tests on consecutive 
visits - then return to regular, 5year screening 
program  
o Otherwise follow-up dependent upon 
outcome of tests 
https://wiki.cancer.org.au/australia/Gui
delines:Cervical_cancer/Screening   
Sweden  2018 o Co-test at 6 months  
o If negative HPV and normal cytology, 
return to screening   
o Otherwise follow-up dependent upon 









Finland  2019 o When most severe histology CIN2+, co-test at 
6 and 24 months 
o If negative HPV and normal cytology, 
follow-up 24 months 
o Otherwise follow-up dependent upon 
outcome of tests 
o When most severe histology ≤CIN1,  co-test at 
6 months 
o If negative HPV and normal cytology, 
return to regular 5-year screening 
o Otherwise follow-up dependent upon 
outcome of tests 
http://www.kaypahoito.fi/web/kh/suo
situkset/suositus?id=hoi50049#K1  
CIN1: cervical intraepithelial neoplasia grade 1; CIN2+: cervical intraepithelial neoplasia 394 
grade 2 or worse; HPV: human papillomavirus 395 
 396 
 397 
